Uso preventivo de antifibrinolíticos em cães

• Autor(a) principal: Maciel, Luis Henrique de Oliveira
• Data de Publicação: 2020
• Tipo de documento: Trabalho de conclusão de curso
• Idioma: por
• Título da fonte: Repositório do Centro Universitário Braz Cubas
• Texto Completo: https://repositorio.cruzeirodosul.edu.br/handle/123456789/1724
• topic: Hemorragia; Tromboelastografia; Hiperfibrinólise; Transfusão; Coagulação; CNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIA::CLINICA E CIRURGIA ANIMAL::ANESTESIOLOGIA ANIMAL

The perioperative blood loss is a common and expected consequence during the surgical act. However, depending on the size of the surgery and the patient's comorbidities, the volume lost may exceed what is expected and bring with it several hemodynamic complications, as well as increase surgical morbidity and mortality and the requirement of transfusion therapy. In this scenario, dogs tend to benefit from prophylactic antifibrinolytic therapy, since, besides the complications of excessive bleeding, tissue trauma can promote the occurrence of coagulopathies, being hyperfibrinolysis, although little diagnosed, the most reported in the canine species. Antifibrinolytics include a plasma protease inhibitor called Aprotinin, and lysine analogs represented by Tranexamic Acid (TA) and Epsilon-Aminocarproic Acid (EACA). However, currently therapy with antifibrinolytics still depends on a correct diagnosis of fibrinolytic activity, since problems in other stages of clot formation will not be solved by these drugs. Even with the creation of increasingly sophisticated tests, as is observed in thromboelastography (TEG) and thromboelastometry (ROTEM®), access to this technology is still limited in the routine of veterinary medicine, while there is a need to obtain equipment for a more immediate analysis. Therefore, the administration of antifibrinolytics in these patients is a promising therapy, but it is still largely done empirically.